Deuterated active pharmaceutical ingredients: A science-based proposal for synthesis, analysis, and control. Part 1: Framing the problem.

导出原文传递

翻译打印收藏纠错

作者： Boris,Czeskis ^[1] ; Charles S,Elmore ^[2] ; Anthony,Haight ^[3] ; David,Hesk ^[4] ; Brad D,Maxwell ^[5] ; Scott A,Miller ^[6] ; Thomas,Raglione ^[6] ; Klaas,Schildknegt ^[7] ; John F,Traverse ^[8] ; Peng,Wang ^[8]

作者单位： Eli Lilly and Company, Indianapolis, Indiana. ^[1] AstraZeneca, Gothenburg, Sweden. ^[2] AbbVie Inc., North Chicago, Illinois. ^[3] Research Triangle Institute, Research Triangle Park, North Carolina. ^[4] Vertex Pharmaceuticals Incorporated, Boston, Massachusetts. ^[5] Bristol-Myers Squibb, New Brunswick, New Jersey. ^[6] Pfizer Inc., Groton, Connecticut. ^[7] Celgene Corporation, Summit, New Jersey. ^[8]

关键词 International Consortium for Innovation & Quality active pharmaceutical ingredient deuterium drug substance isotopologue isotopomer kinetic isotope effect stable-isotope

主题词氘(Deuterium);药用制剂(Pharmaceutical Preparations);科学术语(主题)(Terminology as Topic)

DOI 10.1002/jlcr.3743

PMID 31034626

发布时间 2020-05-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交